

FOI 1310 - Carboprost & 1284 Thiotepa

"...for both thiotepa and carboprost:

- *Number of notifications received between Jan 2018-Dec 2018*
- *Common Dosage form requested (perhaps indicate that 90% of applications were for whatever strength requested)*
- *Common or average duration of use and dose"*

| Product | Number of Notifications | Dosage Form (most common) | Average duration of use and dose |
|-------------------|--------------------------------|----------------------------------|---|
| Carboprost | 1634 | Injection 250mcg/mL | 1 day, dose varied |
| Thiotepa | 122 | Injection 15mg and 100mg | 2 days, dose varied |

Please note,

- The data above refers to SAS A notifications received in the time period 01/01/2018 to 31/12/2018
- The average dose is not calculable due to the variations in product selection (i.e. strength of the product) and the variability in expressing the dosage administered (i.e 1 injection, xmg/kg) within the notification form.